EVGN Earnings Date: Nov 19, 2026 (Estimated) — Evogene Ltd.
NASDAQ · Healthcare · Biotechnology
Updated
When is EVGN's next earnings date?
Evogene Ltd. (EVGN) is expected to report earnings on Thursday, November 19, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.19 on revenue of $365,000.
How did EVGN do in its last earnings report?
In its most recent report on Aug 18, 2026 (Q2 2026), Evogene Ltd. posted EPS of -$0.13 versus the -$0.27 estimate, a beat of 51.8%. Revenue was $347,000 against a $325,000 estimate. The stock's 1-day post-earnings move was +4.0%.
How much does EVGN stock move after earnings?
EVGN beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.9% (up or down) in the day after earnings.
About Evogene Ltd.
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-18 | Q2 2026 | -0.27 | -0.13 | +51.85% | $347,000 | ✅ Beat | +4.04% | -0.18% | -11.46% |
| 2026-05-20 | Q1 2026 | -0.27 | -0.60 | -122.22% | $334,000 | ❌ Miss | -3.24% | -4.57% | -29.42% |
| 2026-03-05 | Q4 2025 | -0.26 | -0.61 | -134.62% | $314,000 | ❌ Miss | -6.16% | -10.39% | -6.47% |
| 2025-11-20 | Q3 2025 | -0.41 | -0.31 | +24.39% | $312,000 | ✅ Beat | -7.69% | -2.99% | -12.83% |
| 2025-08-19 | Q2 2025 | -0.63 | -0.50 | +20.63% | $884,000 | ✅ Beat | -4.22% | -4.22% | -9.13% |
| 2025-03-06 | Q4 2024 | -0.73 | 0.06 | +108.22% | $1.6M | ✅ Beat | -0.23% | -0.96% | -12.99% |
| 2024-11-21 | Q3 2024 | -1.01 | -1.31 | -29.70% | $1.8M | ❌ Miss | -3.03% | +2.24% | -18.18% |
| 2024-08-22 | Q2 2024 | -1.20 | -1.06 | +11.67% | $914,000 | ✅ Beat | -10.80% | -11.31% | -32.16% |
Showing last 8 quarters.